EGRX - Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Eagle Pharmaceuticals Inc. (EGRX) Investors and Encourages Investors to Contact the Firm Before February 9 2024 | Benzinga
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of those who acquired Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) securities during the period from August 8, 2023 through November 28, 2023, inclusive (the "Class Period"). Investors have until February 9, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On November 9, 2023, Eagle announced that it would not release its third quarter 2023 results on time because the Company "requires more time to review potential adjustments relating to the reporting of sales of PEMFEXY prior to filing its Form 10-Q." The Company also disclosed it "expects to revise its previously disclosed 2023 full year guidance downward." On this news, the price of Eagle shares declined by $4.16 per share, or approximately 30.4%, from $13.70 per share to close at $9.54 ...
EGRX) Investors and Encourages Investors to Contact the Firm Before February 9, 2024>Full story available on Benzinga.com